Skip to content

Aktis Oncology, Inc.

AKTS

CIK 0002035832

← back to feed
Revenue (TTM)
—
Q1 Mar 2026
Net Income (TTM)
—
Q1 Mar 2026
EPS Diluted (TTM)
—
Q1 Mar 2026
Gross Margin
—
Q1 Mar 2026
Operating Margin
—
Q1 Mar 2026
Net Margin
—
Q1 Mar 2026
Free Cash Flow (TTM)
—
Q1 Mar 2026
Cash
$371.63M
Q1 Mar 2026
Total Debt
—
Q1 Mar 2026
Shares Outstanding
53.4M sh
Q1 Mar 2026

Recent filings